“You’ll Own Nothing and You’ll Be Happy”

*Sponsored Market Crux Just Initiated Coverage On Silo Pharma, Inc. (Nasdaq: SILO) And It’s Topping Our Watchlist Tomorrow Morning—Wednesday,  May 14, 2025 (SILO) Comes Backed By Several Potential Catalysts Including: (SILO) Just Moved Approximately 51% In One Week, Climbing From $0.74 On May 5 To $1.12 Earlier Today, May 13, Trending Above Several Key Averages. (SILO) Has A Limited Float With Fewer Than 5M Shares—This Could Set The Stage For Significant Swing Potential If Demand Begins To Shift. (SILO) Made An Historic Move From $0.841 To $4.50 In Under  Two Weeks—An Approximate 435% Move In July 2024, That Still  Stands Out On The Chart. (SILO) Appears To Be Flying Under The Radar With Its  Market Cap Below $5M. Get (SILO) On Your Screen Before Tomorrow Morning… May 13, 2025 Dear Reader, Momentum doesn’t always announce itself—it just shows up. You see it in the movement, the pace, and the pressure building beneath an under the radar company. And when it lines up with real developments and a chart with history, it’s worth paying attention. That’s exactly where Silo Pharma, Inc. (Nasdaq: SILO) comes in. Over the past week, it moved approximately 51%, rising from $0.74 on May 5 to $1.12 by May 13, now trending above both its 5- and 20-day moving averages.  With a float under 5M shares and a market cap still below $5M, this is the kind of structure that could set the stage for big swings if demand begins to shift.  Zoom out, and you’ll spot what happened last summer—a move from $0.841 to $4.50 in less than two weeks, marking an approximate 435% run that still stands out on the chart today. That kind of historic breakout potential doesn’t guarantee a repeat—but it does make this technical setup all the more exciting to watch. We’ll have all eyes on (SILO) tomorrow morning… What’s Powering (SILO) Beneath the Surface… While the recent move has brought fresh attention to the name, what’s unfolding inside the company is even more compelling. (SILO) isn’t chasing trends.  It’s targeting long-ignored neurological and mental health conditions with innovative delivery systems and exclusive rights that could potentially change how patients with PTSD, fibromyalgia, Alzheimer’s disease, and multiple sclerosis are treated. And now—with human trials on the near horizon, new patents in hand, and key preclinical milestones achieved—this company has entered a critical phase.  The Building Blocks Behind (SILO)’s Momentum Potential… There’s more than one reason (SILO) is starting to stand out on both scientific and technical radars.  Here are some of the key developments that have positioned the company for increasing visibility in 2025: Silo’s lead program, SPC-15, is advancing through final GLP-compliant studies and could soon enter first-in-human trials.  This patented intranasal compound is designed to deliver targeted effects for PTSD and anxiety by bypassing the blood-brain barrier using nose-to-brain delivery. Both SPC-15 and Alzheimer’s-focused SPC-14 are exclusively licensed from Columbia University, giving (SILO) global rights to develop, manufacture, and commercialize two high-potential compounds in the CNS space. The company has aligned with the FDA to pursue the streamlined 505(b)(2) regulatory pathway—a strategy that may accelerate development timelines and reduce costs for both SPC-15 and SP-26, a chronic pain implant designed for at-home, extended-release ket-a-mine therapy. On the intellectual property front, (SILO) has moved quickly.  In just the first quarter of 2025, it announced multiple patent grants and new filings—strengthening its protection around SPC-15 and opening the door to future combination therapies in stress-related disorders. Backed by Experience. Driven by Results… In a recent shareholder letter, CEO Eric Weisblum shared a more candid view of the road ahead. He emphasized not just the milestones achieved, but the capital discipline (SILO) has maintained—operating debt-free, advancing through development phases without overextension, and expanding only when supported by scientific and regulatory progress. Meanwhile, Dr. James Kuo, a veteran of multiple listed bioscience companies, has taken the helm of Silo’s research and development efforts.  His leadership, alongside a deep bench of advisory board members—including renowned psychiatrist Dr. Charles Nemeroff—signals the company’s intention to build more than a pipeline.  It’s building credibility. Latest Headlines… Silo Pharma (NASDAQ: SILO) has entered a key execution phase in 2025, delivering three notable updates in just a few weeks—each strengthening its clinical trajectory and position in CNS-focused research. April 30, 2025 – SP-26 Hits All Endpoints (SILO)’s extended-release ket-a-mine implant, SP-26, met all preclinical study goals in fibromyalgia, showing strong tolerability, no implant-related issues, and 22-day sustained plasma levels—supporting its path forward as a potential at-home, long-acting treatment for chronic pain. April 28, 2025 – SPC-14 Patent Filed (SILO) filed a U.S. patent for SPC-14, its Alzheimer’s candidate licensed from Columbia University, featuring a dual-receptor mechanism targeting cognitive and neuropsychiatric symptoms—strengthening both the scientific case and its IP position. March 26, 2025 – SPC-15 Advances Toward IND (SILO) began dosing in its final GLP study for SPC-15, an intranasal PTSD therapy, following FDA alignment on the 505(b)(2) pathway—marking the last step before first-in-human trials. With a Clinical Pipeline Like This, Timing Matters With years of research already behind it, (SILO) is no longer just a concept-stage biotech. The timeline to clinical trials is now clear. Following FDA guidance and successful pre-IND developments, SPC-15 may soon transition from lab studies to real-world human use cases. At the same time, the company’s expansion into Alzheimer’s disease and MS research through candidates SPC-14 and SPU-16 demonstrates a broader ambition to make measurable impacts across multiple neurological frontiers—many of which have seen little innovation for decades. This next phase, if executed well, could be where everything changes. As momentum builds, technicals shift, and the company checks off meaningful milestones—there’s a growing sense that (SILO) may no longer stay under the radar. The chart has history.  The pipeline has depth.  And the timing? That’s what makes this one worth watching. Here’s what we’re seeing right now—fact by fact—that has our full focus going into the morning. 5 Reasons Why We Will Have All Eyes On (SILO) Tomorrow Morning… 1. Recent Market Recognition: (SILO) climbed approximately 51% in one week—rising from $0.74 on May 5 to $1.12 early today,  May 13th—while trending above both its 5- and 20-day moving averages. 2. Limited Float: With fewer than 5M shares listed, (SILO) sits in a held range that has historically amplified swing potential when momentum builds. 3. Breakout History: Back in July 2024, (SILO) moved from $0.841 to $4.50 in under two weeks, marking an approximate 435% move that still draws attention when looking at the chart. 4. Flying Under The Radar: Despite clinical progress, new filings, and licensing from Columbia University, (SILO) continues to hold a market cap below $5M as of today. 5. Trial Timeline Advancing: (SILO)’s lead program SPC-15 is in final IND-enabling studies, following FDA alignment for a streamlined clinical path using the 505(b)(2) route. Each of these factors adds weight on its own—but together, they paint a picture that’s hard to ignore. Momentum appears to be building in multiple areas at once—technical, structural, and scientific. And if the name stays on track, this could be one of the more talked-about early-stage biotech setups heading into the summer. Pull Up (SILO) Before Tomorrow Morning… As clinical progress accelerates and technical signals begin to align, Silo Pharma (NASDAQ: SILO) continues to stand out for reasons both structural and scientific.  From its under-the-radar valuation to its tightening float and regulatory momentum, this is a name that has quietly built the foundation for broader recognition. We’ll be watching (SILO) closely early tomorrow. You may want to pull it up before you log off tonight. I’ll have more for you  in the morning—so keep an eye out for my update. Have a good night. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 05/13/2025 and ending on 05/14/2025 to publicly disseminate information about (SILO:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC and their member own shares of (SILO:US). Please see important disclosure information here: https://marketcrux.com/disclosure/silo-9f6mx/#details

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice